Pharmaceuticals targeting nonsense mutations in genetic diseases: Progress in development

BioDrugs

Volumn 23, Issue 3, 2009, Pages 165-174

  Clancy, John P ^a,b,c,d   Rowe, Steven M ^b,c  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ANTIBIOTIC G 418; GENTAMICIN; MESSENGER RNA; NEGAMYCIN; PAROMOMYCIN; PTC 124; TOBRAMYCIN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

BASE PAIRING; BLOOD CLOTTING FACTOR 7 DEFICIENCY; CLINICAL TRIAL; CODON; CYSTIC FIBROSIS; DRUG BIOAVAILABILITY; DRUG DNA BINDING; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG TARGETING; EUKARYOTIC CELL; GENE CONTROL; GENE INTERACTION; GENE REPRESSION; GENE TARGETING; GENE THERAPY; GENETIC DISORDER; HUMAN; MUSCULAR DYSTROPHY; NONHUMAN; NONSENSE MUTATION; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RIBOSOME; STOP CODON; TRANSCRIPTION REGULATION;

AMINOGLYCOSIDES; ANIMALS; CLINICAL TRIALS AS TOPIC; CODON, NONSENSE; CYSTIC FIBROSIS; GENETIC DISEASES, INBORN; HUMANS; MUSCULAR DYSTROPHIES; OXADIAZOLES; PROTEIN BIOSYNTHESIS;

EID: 68649089108     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/00063030-200923030-00003     Document Type: Review

References (77)

1. Kellermayer R. Translational readthrough induction of pathogenic nonsense mutations. Eur J Med Genet 2006 Nov-Dec; 49 (6): 445-50
2. Linde L, Kerem B. Introducing sense into nonsense in treatments of genetic disease. Trends Genet 2008 Nov; 24 (11): 552-63
3. Krawczak M, Ball EV, Fenton I, et al. Human gene mutation database: a biomedical information and research resource. Hum Mutat 2000;15 (1): 45-51
4. Hermann T. Aminoglycoside antibiotics: old drugs and new therapeutic approaches. Cell Mol Life Sci 2007 Jul; 64 (14): 1841-52
5. Schatz A, Bugie E, Waksman SA. Streptomycin, a substance exhibiting antibiotic activity against Gram-positive and Gram-negative bacteria, 1944. Clin Orthop Relat Res 2005 Aug; (437): 3-6
6. Jones D, Metzger HJ, Schatz A, et al. Control of Gram-negative bacteria in experimental animals by streptomycin. Science 1944 Aug 4; 100 (2588): 103-5
7. Moazed D, Noller HF. Interaction of antibiotics with functional sites in 16S ribosomal RNA. Nature 1987 Jun 4-10; 327 (6121): 389-94
8. Hermann T. Drugs targeting the ribosome. Curr Opin Struct Biol 2005 Jun; 15 (3): 355-66
9. Ogle JM, Ramakrishnan V. Structural insights into translational fidelity. Annu Rev Biochem 2005; 74: 129-77
10. Shandrick S, Zhao Q, Han Q, et al. Monitoring molecular recognition of the ribosomal decoding site. Angew Chem Int Ed Engl 2004 Jun 14; 43 (24): 3177-82
11. Francois B, Russell RJ, Murray JB, et al. Crystal structures of complexes between aminoglycosides and decoding A site oligonucleotides: role of the number of rings and positive charges in the specific binding leading to miscoding. Nucleic Acids Res 2005; 33 (17): 5677-90
12. Vakulenko SB, Mobashery S. Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev 2003 Jul; 16 (3): 430-50
13. Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother 1999 May; 43 (5): 1003-12
14. Fischel-Ghodsian N. Genetic factors in aminoglycoside toxicity. Pharmacogenomics 2005 Jan; 6 (1): 27-36
15. Guan MX, Fischel-Ghodsian N, Attardi G. A biochemical basis for the inherited susceptibility to aminoglycoside ototoxicity. Hum Mol Genet 2000 Jul 22; 9 (12): 1787-93
16. Kondo J, Urzhumtsev A, Westhof E. Two conformational states in the crystal structure of the Homo sapiens cytoplasmic ribosomal decoding A site. Nucleic Acids Res 2006; 34 (2): 676-85
17. Kondo J, Francois B, Urzhumtsev A, et al. Crystal structure of the Homo sapiens cytoplasmic ribosomal decoding site complexed with apramycin. Angew Chem Int Ed Engl 2006 May 12; 45 (20): 3310-14
18. Hermann T, Tereshko V, Skripkin E, et al. Apramycin recognition by the human ribosomal decoding site. Blood Cells Mol Dis 2007 May-Jun; 38 (3): 193-8
19. Gorini L, Kataja E. Phenotypic repair by streptomycin of defective genotypes in E. coli. Proc Natl Acad Sci U S A 1964 Mar; 51: 487-93
20. Bonetti B, Fu L, Moon J, et al. The efficiency of translation termination is determined by a synergistic interplay between upstream and downstream sequences in Saccharomyces cerevisiae. J Mol Biol 1995 Aug 18; 251 (3): 334-45
21. Brown CM, Stockwell PA, Trotman CN, et al. Sequence analysis suggests that tetra-nucleotides signal the termination of protein synthesis in eukaryotes. Nucleic Acids Res 1990 Nov 11; 18 (21): 6339-45
22. Keeling KM, Lanier J, Du M, et al. Leaky termination at premature stop codons antagonizes nonsense-mediated mRNA decay in S. cerevisiae. RNA 2004 Apr; 10 (4): 691-703
23. Bedwell DM, Kaenjak A, Benos DJ, et al. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med 1997 Nov; 3 (11): 1280-4
24. Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007 May 3; 447 (7140): 87-91
25. Khajavi M, Inoue K, Lupski JR. Nonsense-mediated mRNA decay modulates clinical outcome of genetic disease. Eur J Hum Genet 2006 Oct; 14 (10): 1074-81
26. Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 1996 Apr; 2 (4): 467-9
27. Keeling KM, Bedwell DM. Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system. J Mol Med 2002 Jun; 80 (6): 367-76
28. Keeling KM, Brooks DA, Hopwood JJ, et al. Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Hum Mol Genet 2001 Feb 1; 10 (3): 291-9
29. Manuvakhova M, Keeling K, Bedwell DM. Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system. RNA 2000 Jul; 6 (7): 1044-55
30. Howard MT, Anderson CB, Fass U, et al. Readthrough of dystrophin stop codon mutations induced by aminoglycosides. Ann Neurol 2004 Mar; 55 (3): 422-6
31. Howard MT, Shirts BH, Petros LM, et al. Sequence specificity of aminoglycoside-induced stop codon readthrough: potential implications for treatment of Duchenne muscular dystrophy. Ann Neurol 2000 Aug; 48 (2): 164-9
32. Bidou L, Hatin I, Perez N, et al. Premature stop codons involved in muscular dystrophies show a broad spectrum of readthrough efficiencies in response to gentamicin treatment. Gene Ther 2004 Apr; 11 (7): 619-27
33. Amrani N, Ganesan R, Kervestin S, et al. A faux 3′-UTR promotes aberrant termination and triggers nonsense-mediated mRNA decay. Nature 2004 Nov 4; 432 (7013): 112-8
34. Wang W, Czaplinski K, Rao Y, et al. The role of Upf proteins in modulating the translation read-through of nonsense-containing transcripts. EMBO J 2001 Feb 15; 20 (4): 880-90
35. Weng Y, Czaplinski K, Peltz SW. Identification and characterization of mutations in the UPF1 gene that affect nonsense suppression and the formation of the Upf protein complex but not mRNA turnover. Mol Cell Biol 1996 Oct; 16 (10): 5491-506
36. Poole E, Tate W. Release factors and their role as decoding proteins: specificity and fidelity for termination of protein synthesis. Biochim Biophys Acta 2000 Sep 7; 1493 (1-2): 1-11
37. Maquat LE. Nonsense-mediated mRNA decay. Curr Biol 2002 Mar 19; 12 (6): R196-7
38. Schell T, Kulozik AE, Hentze MW. Integration of splicing, transport and translationto achieve mRNA qualitycontrol bythe nonsense-mediated decay pathway. Genome Biol 2002; 3 (3): REVIEWS1006
39. Linde L, Boelz S, Nissim-Rafinia M, et al. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. J Clin Invest 2007; 117: 683-97
40. Nudelman I, Rebibo-Sabbah A, Shallom-Shezifi D, et al. Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations. Bioorg Med Chem Lett 2006 Dec 15; 16 (24): 6310-5
41. Kondo J, Hainrichson M, Nudelman I, et al. Differential selectivity of natural and synthetic aminoglycosides towards the eukaryotic and prokaryotic decoding A sites. Chembiochem 2007 Sep 24; 8 (14): 1700-9
42. Hainrichson M, Nudelman I, Baasov T. Designer aminoglycosides: the race to develop improved antibiotics and compounds for the treatment of human genetic diseases. Org Biomol Chem 2008 Jan 21; 6 (2): 227-39
43. Arakawa M, Shiozuka M, Nakayama Y, et al. Negamycin restores dystrophin expression in skeletal and cardiac muscles of mdx mice. J Biochem 2003 Nov; 134 (5): 751-8
44. Barton-Davis ER, Cordier L, Shoturma DI, et al. Aminoglycoside antibiotics restore dystrophin functiontoskeletal musclesofmdx mice.JClin Invest 1999 Aug; 104 (4): 375-81
45. Du M, Jones JR, Lanier J, et al. Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgene. J Mol Med 2002; 80 (9): 595-604
46. Du M, Keeling KM, Fan L, et al. Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gen-tamicin in a transgenic CF mouse model. J Mol Med 2006 Jul; 84 (7): 573-82
47. Du M, Liu X, Welch EM, et al. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci U S A 2008 Feb 12; 105 (6): 2064-69
48. Wilschanski M, Dupuis A, Ellis L, et al. Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. Am J Respir Crit Care Med 2006 Oct 1; 174 (7): 787-94
49. Wilschanski M, Yahav Y, Yaacov Y, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 2003 Oct 9; 349 (15): 1433-41
50. Wilschanski M,FaminiC, Blau H,et al.A pilot study ofthe effectofgentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med 2000 Mar; 161 (3 Pt 1): 860-5
51. Clancy JP, Bebok Z, Ruiz F, et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 2001 Jun; 163 (7): 1683-92
52. Sermet-Gaudelus I, Renouil M, FajacA, etal. Invitro predictionofstop- codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study. BMC Med 2007; 5: 5
53. Clancy JP, Rowe SM, Bebok Z, et al. No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. Am J Respir Cell Mol Biol 2007 Jul; 37 (1): 57-66
54. Clancy JP, Konstan MW, Rowe SM, et al. A phase II study of PTC124 in CF patients harboring premature stop mutations [abstract]. Ped Pulmonol Suppl 2006; 41 (S29): 269
55. Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008 Aug 30; 372 (9640): 719-27
56. Politano L, Nigro G, Nigro V, et al. Gentamicin administration in Duchenne patients with premature stop codon: preliminary results. Acta Myol 2003 May; 22 (1): 15-21
57. Pinotti M, Rizzotto L, Chuansumrit A, et al. Gentamicin induces subtherapeutic levels of coagulation factor VII in patients with nonsense mutations. J Thromb Haemost 2006 Aug; 4 (8): 1828-30
58. Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008 Aug 30; 372 (9640): 719-27
59. Rowe SM, Varga K, Rab A, et al. Restoration of W1282X CFTR activity by enhanced expression. Am J Respir Cell Mol Biol 2007 Sep; 37 (3): 347-56
60. Linde L, Boelz S, Nissim-Rafinia M, et al. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. J Clin Invest 2007 Mar; 117 (3): 683-92
61. Rowe SM, Accurso F, Clancy JP. Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials. Proc Am Thorac Soc 2007 Aug; 4 (4): 387-98
62. Pedemonte N, Lukacs GL, Du K, et al. Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 2005 Sep; 115 (9): 2564-71
63. Van Goor F, Straley KS, Cao D, et al. Rescue of deltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 2006 Jun; 290 (6): L1117-30
64. Sermet-Gaudelus I, De Boeck C, Casimir G, et al. Children with nonsense-mutation-mediated cystic fibrosis response to investigational treatment with PTC124 [abstract]. Ped Pulmonol Suppl 2008; 31: 294
65. Kerem E, Yaacov Y, Armoni S, et al. PTC124 induces time-dependent improvements in chloride conductance and clinical parameters in patients with nonsense-mutation-mediated cystic fibrosis [abstract]. Ped Pulmonol Suppl 2008; 31: 294
66. Accurso FJ, Rowe SM, Durie PR, et al. Interim results of phase 2A study of VX-770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D [abstract]. Ped Pulmonol Suppl 2008; 31: A267
67. Wilschanski M, Armoni S, Yaacov Y, et al. PTC124 treatment over 3 months improves pharmacodynamic and clinical parameters in patients with nonsense-mutation-mediated CF [abstract]. J Cystic Fibrosis 2008; 7Suppl. 2; S22
68. Wagner KR, Hamed S, Hadley DW, et al. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann Neurol 2001 Jun; 49 (6): 706-11
69. PTC Therapeutics. Safety and efficacy study of PTC124 in Duchenne muscular dystrophy [clinicaltrials.gov identifier no. NCT00264888; online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00264888?id= NCT00264888&rank=1 [Accessed 2009 Apr 9]
70. Hein LK, Bawden M, Muller VJ, et al. Alpha-L-iduronidase premature stop codons and potential read-through in mucopolysaccharidosis type I patients. J Mol Biol 2004 Apr 30; 338 (3): 453-62
71. PTC Therapeutics. Phase 2b study of PTC124 in Duchenne/Becker muscular dystrophy (DMD/BMD) [clinicaltrials.gov identifier no. NCT00592553; online] Available from URL: http://clinicaltrials.gov/ct2/show/NCT00592553?term =NCT+00592553&rank=1 [Accessed 2009 Feb 12]
72. Sleat DE, Sohar I, Gin RM, et al. Aminoglycoside-mediated suppression of nonsense mutations in late infantile neuronal ceroid lipofuscinosis. Eur J Paediatr Neurol 2001; 5 Suppl. A: 57-62
73. Wolstencroft EC, Mattis V, Bajer AA, et al. A non-sequence-specific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels. Hum Mol Genet 2005 May 1; 14 (9): 1199-210
74. Schulz A, Sangkuhl K, Lennert T, et al. Aminoglycoside pretreatment partially restores the function oftruncated V(2) vasopressin receptors foundin patients with nephrogenic diabetes insipidus. J Clin Endocrinol Metab 2002 Nov; 87 (11): 5247-57
75. Kellermayer R, Szigeti R, Keeling KM, et al. Aminoglycosides as potential pharmacogenetic agents in the treatment of Hailey-Hailey disease. J Invest Dermatol 2006 Jan; 126 (1): 229-31
76. Helip-Wooley A, Park MA, Lemons RM, et al. Expression of CTNS alleles: subcellular localization and aminoglycoside correction in vitro. Mol Genet Metab 2002 Feb; 75 (2): 128-33
77. Lai CH, Chun HH, Nahas SA, et al. Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. Proc Natl Acad Sci U S A 2004 Nov 2; 101 (44): 15676-81